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Pharmaceutical Crystallization with Nanocellulose Organogels 
Celia Ruiz Palomero
a
, Stuart R. Kennedy
b
, M. Laura Soriano
a
, Christopher D. Jones
b
, Miguel 
Valcárcel
*a
 and Jonathan W. Steed
*b
Carboxylated nanocellulose forms organogels at 0.3 wt% in the 
presence of a cationic surfactant. The resulting gels can be used as 
novel crystallization media for pharmaceutical solid form control, 
resulting in isolation a new sulfapyridine solvate, morphology 
modification and crystallization of an octadecylammonium salt of 
sulfamethoxazole. 
The solid form of active pharmaceutical ingredients (APIs) 
continues to be of tremendous intellectual and commercial 
interest.
1-5
 The solid forms of a drug, which can be crystalline, 
co-crystalline, solvate or amorphous,
6-9
 can have different 
solubility, bioavailability, stability and processing 
characteristics.
1, 10
 They also offer drug manufacturers new 
intellectual property opportunities.
3, 11, 12
 As a result the solid 
state chemistry of drug substances is far more intensively 
studied than most other molecular compounds. Generally new 
drug candidates undergo one or more rounds of solid form 
screening. While solid form screens are routine and can be 
undertaken relatively quickly, the reports of late-appearing, 
insoluble and hence more thermodynamically stable 
polymorphs of drugs such as ritonavir
13
 means that there is 
enduring interest in novel crystallization methods. 
Crystallization of a drug substance from common solvents may 
well readily reveal a variety of solid forms
1
 but crystallization 
strategies that can expand the solid form screening space 
beyond conventional methodology
14
 offers the opportunity to 
reveal hard-to-nucleate or slow-growing crystal forms. The 
issue is particularly topical since many computational crystal 
structure calculation approaches predict far more feasible 
polymorphs than are actually observed in practice.
15, 16
 High-
throughput approaches offer a greater chance of finding less-
accessible polymorphs.
17
 Other novel approaches to solid form 
discovery include crystallization in microemulsion droplets,
18, 19
 
polymer microgels,
20
 under nanoscale confinement
21
 and 
epitaxial overgrowth on a related parent phase.
22
 In addition, 
recent work by ourselves and others
23-26
 has begun to develop 
a variation on the classical technique of crystallization from 
polymer hydrogels such as silica or agarose. By using small-
molecule supramolecular gels this work has shown that gel 
phase crystallization can move from water to organic solvents 
and the gelation process can be made to be reversible under 
mild conditions through the use of competing supramolecular 
interactions such as anion binding.
23, 27-29
 The potential 
advantages of this supramolecular organogel crystallization 
approach include diversity in solvent choice, the elimination of 
convection and the possibility of directed crystallization based 
on the local periodicity of the gel fibres.
30
 The controlled 
reversibility of the gelation process potentially allows for facile 
recovery of the gel-grown samples. 
 Nanocellulose (NC) exhibits a range of interesting 
properties such as a highly functionalised surface, a 
filamentous structure lending itself to gelation behaviour, high 
porosity, low coefficient of thermal expansion, optical 
transparency and interesting self-assembly behaviour. It is also 
an abundant and cheap material which has led to tremendous 
interest in the development of NC composites.
31-34
 
Functionalised NC has promising properties as an active 
absorbent in analytical applications.
35
 In the present work we 
report the adaptation of functionalised nanocellulose for 
application as an organogel pharmaceutical crystallization 
medium. 
Results and Discussion 
Carboxylated nanocellulose (c-NC) can be prepared from 
microcrystalline cellulose by radical oxidation using the 
2,2,6,6-tetramethylpiperidine-1-oxyl radical (TEMPO) and 
NaOCl.
36
 The oxidation process serves to disrupt the extensive 
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inter-strand hydrogen bonding in microcrystalline cellulose 
and give separated nanocellulose filaments. The resulting c-NC 
forms an opaque hydrogel at around 9% by weight (see 
supplementary information, Figure S1) but is insoluble in most 
common organic solvents.
35
 For use as a pharmaceutical 
crystallization medium for relatively hydrophobic drugs with 
low water solubility we sought a simple strategy to render the 
resulting c-NC filaments more hydrophobic. We reasoned that 
pairing the surface carboxylic acid functionalities with organic 
primary ammonium cations should sheath the c-NC filaments 
in a hydrophobic coating rendering them soluble in organic 
solvents while also serving to isolate the filaments from one 
another and hence promote gelation properties. Gelation tests 
of c-NC in the presence of lipophilic amines were carried out in 
a range of organic solvents (toluene, chloroform, ethyl acetate, 
acetone, dimethyl sulfoxide (DMSO), dimethylformamide, 
ethanol, tetrahydrofuran, ethylene glycol, picoline, pyridine, 
nitrobenzene, dichlorobenzene and nitromethane). The 
following amines were used as c-NC solubilizers: 
undecylamine, dodecylamine, nonylamine, octadecylamine 
(OD), octylamine, amylamine, cyclopentylamine, 
tetrahydrofufurylamine and 3-dimethylamino-1-propylamine. 
In general the majority of these experiments did not result in 
solubilisation of the c-NC. However the combination of the 
longest chain amine, octadecylamine, with c-NC in DMSO 
resulted in the formation of a robust, translucent gel. The gel 
was produced by vortexing and heating a solution of c-NC in 
the presence of amine in conjunction with brief (10 s) 
sonication
37
 in ultrasound bath. Gelation occurred on cooling 
to room temperature under ambient conditions. Optimisation 
of the gel revealed a critical gelation concentration of 0.3 wt% 
with 3 mg c-NC and 5 mg octadecylamine in 1 mL DMSO 
(Figure 1a). The gel is thermoreversible with a Tgel of 58 
o
C 
(dropping ball method). The gel-sol transition is also observed 
as an endothermic transition by DSC with an onset 
temperature of 50 
o
C and a peak at 55 
o
C (supplementary 
information, Figure S2). 
 The new OD/c-NC gel was dried under vacuum for 2 days, 
coated with 3nm chromium and imaged by SEM which 
revealed an unusual structure involving an entangled sheet-
like morphology, (Figure 1b – see SI for further SEM images). 
The gel was also analysed by stress sweep rheometry. Gels 
were formed in a lipless glass vial and then transferred to the 
rheometer in flat plate geometry and allowed to stabilise. The 
samples reached a maximum elastic modulus G′ of 73,000 Pa 
with G′′ of 2,000 Pa. Gels yielded at a stress of 250 Pa. The fact 
that G′ is more than an order of magnitude greater than G′′ 
confirms the solid-like nature of the materials and confirms 
they are true gels (Figure 1c).
38
 
 The carboxylic acid residues on the OD/c-NC gels have the 
potential to interact strongly with the hydrogen bonding 
functionality of drug-like molecules, effectively locally 
immobilising the drug substances on the surface of the gel 
fibre and providing a nucleation surface. Accordingly the 
crystallization of a variety of examples of drugs and drug-like 
molecules bearing carboxylic acid, amide and nitrogen 
heterocyclic functionality within the novel DMSO OD/c-NC gel 
was examined. The targets chosen were dopamine 
hydrochloride, mexiletine hydrochloride, p-aminohippuric acid, 
benzocaine, sulfapyridine, L-valine, hydrochlorothiazole, 4-
aminopyridine, 5-aminosalicylic acid, carisoprodol, isoniazid, 
ethonamide, sulfamethazine, sulfamerazine, sulfamethoxazole 
and sulfadiazine. As a control experiment identical 
crystallizations were also undertaken on pure DMSO without 
the gel. Mixtures of drug substance (10 – 500 mg) with 3 mg c-
NC in the presence of OD were warmed in 1 mL DMSO and 
then allowed to cool to room temperature upon which 
gelation occurred. Gel formation was observed for all drug 
substances with the exception of 5-aminosalicylic acid and 
sulfathiazole which completely prevented gelation. In general 
many drugs weakened the gels. In the case of sulfapyridine 
and sulfamethoxazole this was confirmed by stress sweep 
rheometry with G′ values for the drug-gel mixture below 1000 
Pa and yield stress of only 5 Pa in the presence of excess drug 
substance (see SI Figure S3). In the presence of very large 
excesses (e.g. 500 mg mL
-1 
of dopamine hydrochloride, 
mexiletine hydrochloride and aminohippuric acid) many drug 
substances completely inhibited gelation. We attribute this 
effect to factors such as increasing concentration of ions in 
solution and changes in pH disrupting the interactions 
between the gelators themselves and is analogous to the 
effect of added anions on the strength of supramolecular 
gels.
39, 40
 
 In the case of sulfapyridine large, colourless block-like 
crystals formed within the gels upon standing at room 
temperature at concentrations in excess of 100 mg mL
-1
, 
however no crystallization occurred under the same conditions 
in the pure DMSO control experiments. These crystals were 
analysed by single crystal X-ray diffraction and proved to be a 
new 1:1 DMSO solvate (see supplementary information, Figure 
S4). Sulfapyridine is an extensively studied antibacterial Figure 1. (a) Optimised octadecylamine/c-NC gel in DMSO at 0.3 wt%. (b) SEM image 
of the OD/c-NC xerogel showing the layered structure. (c) Stress sweep rheometry of 
the OD/c-NC DMSO gel. 
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discovered by May and Baker in 1937 and used in the second 
world war, not least to treat Winston Churchill’s pneumonia.
41
 
It exists in nine pure polymorphic forms
42-44
 and the CSD 
contains entries for 1:1 solvates with dioxane, tetrahydrofuran 
and nitromethane as well as a co-crystal with oxalic acid 
dibutyl ester and a piperidinium salt. The new form is 
isomorphous with the previously reported nitromethane 
solvate
45
 with the DMSO molecules situated in a discrete 
pocket in the structure arising from the V-shape of the 
sulfapyridine molecules, Figure 2. The sulfapyridine is in the 
common imide form
44
 and forms hydrogen bonded dimers 
linked to the adjacent molecule by hydrogen bonding from 
the amino group to the sulfonyl oxygen atoms.  
 While the structure itself is unremarkable, the fact that the 
c-NC gel reproducibly induces crystallization of such a 
well-studied compound from a solvent in which it does not 
crystallize in the absence of the gel indicates that the gel has a 
marked influence on the crystallization behaviour of the 
material. The equilibrium solubility of sulfapyridine in DMSO at 
room temperature is around 5 mM or 1.25 mg mL
-1
,
46
 and 
hence both gel and solution crystallizations are highly 
supersaturated. As a result the gel must be acting as a kinetic 
nucleation promoter rather than thermodynamically ‘salting 
out’ the solute.
47
  
 Crystals suitable for single crystal X-ray diffraction were 
also isolated from c-NC gels for the anti-tuberculosis drug 
isoniazid. The diffraction results revealed that this crystals are 
of the one known polymorph of isoniazid.
48
 The crystals were 
obtained from both the gel and the solution control 
experiments, however those from the gel were larger and 
better formed. The solution grown crystals adopt a needle-like 
habit, while the gel grown samples adopt a block morphology, 
Figure 3, suggesting specific interactions of the growing crystal 
with the c-NC. 
Crystallization of another sulfa-antibiotic sulfamethoxazole 
from the OD/c-NC DMSO gels (see supplementary information, 
Figure S5) resulted in the formation of a surprising 
octadecylammonium salt of deprotonated sulfamethoxazole as 
a 1:2 DMSO solvate. The structure adopts an interdigitated 
lipid bilayer type arrangement with a polar region comprising 
DMSO solvent bridged sulfamethoxazole dimers, linked by 
hydrogen bonding from the amine NH groups to the DMSO 
oxygen atoms. The octadecylammonium ions interact with the 
sulfamethoxazole anions via hydrogen bonding to the sulfonyl 
oxygen atoms, Figure 4. The crystallization of this large 
structure of a flexible long chain ammonium salt is relatively 
surprising. While crystals were not obtained in the absence of 
the c-NC gel it is not clear if the gel plays a direct role in the 
formation of this material. However, the structure does 
suggests a possible role for the ammonium-ion-sheathed gel in 
immobilising solutes by ion pairing via the formation of 
intercalated lipid bilayers on the fibre surface.  
 In a further attempt to develop novel NC based 
crystallization media we also prepared sulfonated 
nanocellulose (s-NC) according to the published procedure.
49
 
The s-NC forms organogels in DMSO at 0.8 wt% (see 
supplementary information, Figure S6). These gels were used 
to crystallize sulfapyridine and also resulted in the formation 
of the new 1:1 DMSO solvate. 
 In conclusion we have shown that a readily available, 
Figure 2. X-ray crystal; structure of the 1:1 DMSO sulfapyridine solvate isolated from a 
nanocelluose gels showing the solvent pocket and principal hydrogen bonding 
interactions. 
Figure 4. X-ray crystal structure of he octadecylammonium salt of deprotonated sulfamethoxazole 1:2 DMSO solvate isolated from a nanocelluos  gels showing the solvent 
bilayer arrangement of the octadeculammonium ions. 
Figure 3. (a) Needle crystals of isoniazid grown from DMSO solution and (b) block 
shaped crystals from DMSO OD/c-NC gels under the same conditions. 
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hydrophilic nanomaterial can be modified to give an effective 
organogelator with low critical gelation concentration by 
addition of a cationic surfactant. The resulting hybrid 
organogels are suitable for use as a novel crystallization 
method for a range of pharmaceuticals. The effects of the gel 
are generally to eliminate convection effects and promote 
crystallization possibly by enhancing nucleation rate. Gel 
grown crystals are generally better formed. In the well-known 
systems studied here the gel medium has resulted in novel 
results, namely formation of a new solvate crystal form, habit 
modification and crystallization of a salt of a flexible long-chain 
surfactant. Novel organogel media offer considerable promise 
for application as part of an advanced solid forms 
pharmaceutical screening approach, particularly in the search 
for hard to nucleate or kinetically unfavourable solid forms. 
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